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Trastuzumab-based regimes improved clinical outcome in women with overexpressing HER2 metastatic breast cancer, mainly due
to the availability of diﬀerent combination therapies, clinically active and well tolerated. In this study we retrospectively evaluated
clinical activity and toxicity of trastuzuamb plus gemcitabine regimen in heavily pretreated HER2 positive metastatic breast cancer
patients.Althoughtheobservedpopulationwasheavilypretreated,theevaluatedregimenwasnotablyeﬀectiveintermsofresponse
rate, time to progression and survival, with very mild toxicity. These data suggest that in over expressing HER2 metastatic breast
cancer patients, sequential trastuzumab based chemotherapeutic regimens can achieve good response rate with prolonged TTP in
responding patients, even after other target therapy such as lapatinib based combinations.
1.Introduction
Humanepidermalgrowthfactorreceptor2(HER2)isatrans-
membranetyrosinekinasewhichiscrucialincellgrowthand
diﬀerentiation.
T h eH E R 2g e n ei sa m p l i ﬁ e di n1 5 – 2 0 %o fh u m a nb r e a s t
cancers, and this feature is a well-known poor prognostic
factor [1–3].
Trastuzumab (Herceptin Roche, Basel, Switzerland), a
humanised monoclonal antibody with speciﬁcity for HER2,
changed the natural history of HER2 overexpressing breast
cancer,in theadjuvantsetting aswellasin metastatic disease.
After phase II studies, the results of important phase III
randomized trial enabled the registration of regimen of
weekly paclitaxel plus trastuzumab by Food and Drug Ad-
ministration (FDA) for HER2-positive metastatic breast
cancer (MBC) [4–7].
Although the combination of taxane with trastuzumab is
considered the reference regimen for HER2 overexpressing
MBC, other combination therapies were evaluated in exten-
sive phase II trials [8].
In patients with progressive disease after ﬁrst-line
trastuzumab-based regimens, a current clinical practice is
to continue trastuzumab changing the chemotherapeutic
partner.
Therefore, the identiﬁcation of diﬀerent combinations of
trastuzumab-based regimens for sequential use is important.
I nap r e v i o u ss t u d y ,w et e s t e de ﬃcacy and tolerability
of trastuzumab plus vinorelbine (VNR) regimen in ﬁrst-
and second-line setting for HER2 overexpressing MBC, with
value for response rate (RR) of 78%, median time to pro-
gression (TTP) of 9 months, and median overall survival
(OS) of 28 mounths. Very mild toxicity was observed [9].
Our results were in agreement with those previously
published [10–19]. They were recently conﬁrmed in two
prospective and randomized trials, such as TRAVIOTA
Study and HERNATA study, where the trastuzumab plus
VNR regimen was not inferior then trastuzumab plus2 Journal of Oncology
docetaxel/paclitaxel regimen in terms of anticancer activity
and had less signiﬁcant adverse events in ﬁrst-line setting
[20, 21].
Basedonpreclinicalstudiesindicatingsynergisticactivity
originated by trastuzumab and gemcitabine (GEM) [22]a n d
considering phase II study, where trastuzumab plus GEM
regimen was eﬀective and well tolerated [23], we chose this
combination for pre treated patients in our clinical practice.
In our study, the outcome of patients treated with tra-
stuzumab/GEM regimen was retrospectively evaluated in
order to asses the eﬃcacy and the tolerability of this regimen.
This retrospective study was approved by the local In-
stitution Review Board. The ﬁndings are the subject of the
present report.
2. Patientsand Methods
We obtained, from our central pharmacy data base, the list
of women with metastatic breast cancer HER2 3+ by IHC,
or 2+ and positive for HER2 gene ampliﬁcation, treated with
GEM 1250mg/m2 on days 1 and 8 of a 21-day cycle plus
trastuzumab 4mg/kg loading dose and then 2mg/kg weekly.
The main characteristics of treated patients are reported
in Table 1. Sixty percent of patients had received three or
more previous chemotherapy regimens for metastatic dis-
ease and 28% two-chemotherapy regimens, including tra-
stuzumab-based chemotherapy (90%) and lapatinib plus
capecitabine (41%).
Sixty-nine percent of patients had more than two meta-
static sites, one visceral site was reported for 7% of popula-
tion, bone only for 7% and nodal and/or soft tissue for 17%
of patients.
Metastasis to Central Nervous System (CNS) was present
in 14% of patient’s population, under clinical control after
radiation therapy.
We used a 21-day cycle, with trastuzumab given weekly
at a loading dose of 4mg/kg intravenously (IV) over 90
minutes, and at 2mg/kg IV in 30 minutes thereafter.
To avoid infusion syndrome, the ﬁrst trastuzumab infu-
sion was premedicated with chlorphenamine 100mg IV and
patients were monitored for 60 minutes after infusion.
GEM was given at the dose of 1250mg/m2 on days 1 and
8 of 21-day cycle on the same day, after the infusion of tra-
stuzumab.
Complete blood counts with diﬀerential were obtained
weekly and liver and renal tests were performed every 3
weeks.
Tumour marker, Ca 15-3, was performed periodically if
it was elevated at the beginning of the treatment.
The dose of GEM was reduced by 50% if neutrophil
absolute count ranged between 1,000 and 1,500/mL. and it
was omitted in case of lower neutrophil values.
No trastuzumab dose modiﬁcation was foreseen for low
neutrophil absolute counts.
No other concomitant antineoplastic treatment was de-
livered,exceptbisphosphonatesforwomenwithbonemetas-
tases.
According to our clinical practice, tumour response was
assessed every 3 cycles, performing the clinical and radiolog-
ical examinations.
Thetherapylasteduntilunacceptabletoxicityorprogres-
sion.
Response and toxicity were assessed according to WHO
standard and NCI criteria [24, 25].
By retrospective analysis, primary end points were RR
and TTP, calculated from the ﬁrst day of therapy until pro-
gression or relapse.
Secondary end points were median duration of response,
e s t i m a t e df r o md a t eo fd o c u m e n t e dc o m p l e t er e s p o n s e( C R )
orpartialresponse(PR)untilrelapseorprogression,andOS,
calculated from the beginning of therapy until death.
3. Results
A median number of 7 cycles of trastuzumab/GEM regi-
men were delivered (range 2–17). Forty-one patients were
assessed for response and toxicity. Table 2 shows tumour
response. We observed 1 CR (3%) and 18 PRs (44%) for an
overall 47% RR. Stable disease (SD) longer than 6 months
was observed in 7 patients (17%), for an overall clinical
beneﬁt (CR+PR+SD) of 64%. Fifteen patients progressed
(36%).
No diﬀerence was noted about visceral and not visceral
disease. Median duration of PR was 6 months (95% CI, 1,5–
18 months) and one CR lasted 10 months. Median TTP and
OS are reported in Figures 1 and 2.
InthewholepopulationmedianTTPwas8months(95%
CI, 3–12) and median OS was 20 months (95% CI, 13–38).
The toxicity of 21 day regimen was very mild. No toxicity of
grade 4 was detected. Neutrophil absolute counts were less
than 1000/µL only for seven patients (17%) and omission of
scheduled GEM dose was applied.
In these cases, we did not observe neutropenic fever and
spontaneous recovery occurred promptly, without support-
ive measures or clinical complications.
For ﬁve patients (12%) the dose of GEM was reduced to
80% during the duration of therapy, due to frequent reduc-
tions and omissions of the planned dose of GEM.
NonhaematologicaltoxicitywasmildandnoG3or4tox-
icities were reported.
Gastrointestinal side eﬀects, such as nausea/vomiting or
stomatitis were mild and no alopecia was reported, which
increased compliance to treatment.
4. Discussion
Trastuzumab-based regimen improved clinical outcome of
women with HER2 overexpressing MBC, mainly due to the
availability of diﬀerent combination regimens, clinically
active, and well tolerated.
Phases II and III trials have demonstrated the activity
and safety of trastuzumab administered with chemotherapy,
including weekly taxane, as well as VNR, platinum salts,
GEM, and a variety of other combinations.Journal of Oncology 3
Table 1: Patient’s characteristics.
N %
No. of patients 41 100
Median age 54 (33–75)
PS (ECOG)
0 30 73
1 11 27
Histology
Ductal 36 88
Lobular 51 2
Hormonal Receptor status
EgR+PgR+ 24 58
EgR+PgR− 41 0
EgR−PgR+ 12
EgR−PgR− 12 29
HER2 Status
3+ 32 78
2+CISH+ 92 2
Stage at diagnosis
I 37
IIA 82 0
IIB 25
IIIA 16 39
IIIB 51 2
IIIC 51 2
IV 25
Metastatic site
Nodal involvement ±soft tissue 71 7
As bone only 37
1 visceral site (liver, lung, and pleura) only 37
Metastatic sites ≥ 2 28 69
Metastasis to CNS 61 4
Prior adjuvant CT 38 92
Adjuvant trastuzumab 37
Prior CT for metastatic disease 41 100
1r e g i m e n 51 2
2 regimens 11 28
≥3 regimens 25 60
Prior trastuzumab −based CT 37 90
Prior lapatinib +capecitabine 17 41
ECOG: Eastern Cooperative Oncology Group, EgR: Estrogen Receptor, PgR: Progesteron Receptor, CISH: Chromogenic In Situ Hybridisation, CT:
Chemotherapy, CNS: Central Nervous System.
Today, the optimal trastuzumab-based regimen and the
appropriate sequencing of these combination therapies are
not know.
The choice of the regimen to treat the HER2-positive pa-
tients has to consider previous chemotherapy regimens and
the risk beneﬁt ratio of these therapies [26].
Although the combination of taxane with trastuzumab is
considered the reference therapy for HER2 overexpressing
MBC, the recent published data of Traviota and Hernata
study support the use of trastuzumab plus weekly VNR, as
appropriateﬁrst-lineregimen,aswellassecond-lineregimen
[9–21].
In a recent study, Yardley investigated the activity and
toxicity of combination therapy with trastuzumab and GEM
as ﬁrst- and second-line treatment for patients with HER2
overexpressing MBC and this regimen appears less active
than trastuzumab in combination with either taxanes or
VNR, with RR of 30% and TTP of 4 months [27].4 Journal of Oncology
Table 2: Tumor Response (n = 41).
N %
Overall response 19 47
Complete response 1 3
Partial response 18 44
Stable disease ≥ 6m o n t h s 7 1 7
Clinical beneﬁt 26 64
Progression 15 36
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Figure 1: TTP (Time to progression).
In phase II trial, O’Shaughnessy described a RR of 44%,
with TTP and OS of 5,8 and 14,7 months, respectively for
combination of trastuzumab and GEM in pre-treated HER2
positive MBC, with very mild toxicity [23].
Even with the limitations arising from retrospective
character of our analysis, our results agree to those which
reported RR of 47%, TTP of 8 months and OS of 20 months
and conﬁrm that the regimen evaluated is eﬀective and well
tolerated, even in this heavily pretreated population.
Notably, all patients that showed PRs were pretreated
by trastuzumab-based regimens mostly trastuzumab plus
weekly paclitaxel or trastuzumab plus weekly VNR, or both.
Among 17 pretreated patients also by lapatinib plus
capecitabine, we described 11 PRs (65%) and 4 SD (23%)
with a clinical beneﬁt of 88%, while two patients progressed
(12%).
The unique CR was reported in a patient pretreated in
ﬁrst line by docetaxel 21 day regimen and by weekly trastuz-
umab and VNR as second line chemotherapy.
This CR occurred in patient with locoregional disease
and lasted 10 months.
To continue trastuzumab-based regimen after disease
progression is still debated, due to a substantial lack of scien-
tific evidence, since randomized studies adequately powered
have not been completed.
Recently, von Minckwitz et al. reported results of the ﬁrst
randomizedtrial,assigningpatientswhoexperienceprogres-
sion while receiving a trastuzumab-containing regimen, to
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Figure 2: OS (overall survival).
stop or continue this antibody with the institution of cape-
citabine therapy [28].
They enrolled 78 patients per arm, and although this
number is much less than the 482 intended; they showed a
better TTP in favour of combination (5.6 versus 8.2 months;
P = .0338), and better RR with doublet therapy (27% versus
48%; P = .0115), but OS was not statistically signiﬁcant.
The small number of patients in this trial was due to
slowly accrual and early closing, because of availability of
lapatinib plus capecitabine data [29], and it limited the
statistical power of these observations.
Although deﬁnitive data in this setting are lacking, it
is becoming clear that to continue HER2 blockade is very
important in patients with HER2 overexpressing MBC, and
cliniciansoftenreinstitutetrastuzumabcombinedwithother
cytotoxic drugs after progression on lapatinib based therapy.
With increasing evidence of activity of newer com-
pounds, such as trastuzumab-DM 1 [30], pertuzumab
[31], and neratinib [32], we will have to ﬁgure out the
best sequence of these therapies, identify mechanisms of
resistance, and then ﬁnd a way to individualize therapy.
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